| 000 | 01062 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250518090325.0 | ||
| 264 | 0 | _c20210121 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1744-764X | ||
| 024 | 7 |
_a10.1080/14740338.2020.1737673 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aParikh, Simy K | |
| 245 | 0 | 0 |
_aA comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine. _h[electronic resource] |
| 260 |
_bExpert opinion on drug safety _cMay 2020 |
||
| 300 |
_a537-543 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aCalcitonin Gene-Related Peptide _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMigraine Disorders _xphysiopathology |
| 700 | 1 | _aBurkett, John G | |
| 700 | 1 | _aSilberstein, Stephen D | |
| 773 | 0 |
_tExpert opinion on drug safety _gvol. 19 _gno. 5 _gp. 537-543 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14740338.2020.1737673 _zAvailable from publisher's website |
| 999 |
_c30690410 _d30690410 |
||